successfully completed<\/a> in May \u2013 involving young adults facing increased infection risks from living or working in crowded environments.<\/p>\nVaccine investments<\/p>\n
Biointelect Venturer is a national vaccine and infectious disease incubator funded via the federal government\u2019s Medical Research Future Fund.<\/p>\n
General manager Danielle Shand said the program was designed to help Australian infectious disease companies bridge the gap between research and commercial readiness. ENA is one of six infectious disease biotech companies sharing in $10.48 million to accelerate their commercialisation potential.<\/p>\n
The others are: SAMMvax, has createda vaccine to provide broad protection against Strep A; Saccharide Therapeutics, which is developing a new malaria vaccine (a disease that kills more than 600,000 people annually); Ebivanta Therapeutics, which is is developing an mRNA vaccine against Epstein\u2013Barr virus; Proboxis Biotechnology, which is also developing a vaccine production platform for mosquito-borne viruses,\u00a0 beginning with Japanese encephalitis; and AdaptiVax, which is developing an adaptable virus-like particle (VLP) vaccine platform technology designed to\u00a0 enable the rapid development of vaccines against multiple respiratory viruses. The platform\u2019s initial application\u00a0 targets three viruses \u2013 RSV, human metapneumovirus and parainfluenza virus. These represent the three major\u00a0 causes of respiratory illness and hospitalisation, particularly among young children and older adults. If\u00a0 successful, the vaccine could not only protect against all three viruses, but the broader AdaptiVax platform\u00a0 could also support the development of vaccines against other RNA viruses, helping to strengthen Australia\u2019s\u00a0 vaccine manufacturing capability and preparedness for future respiratory disease threats.\u00a0<\/p>\n
Biointelect Venturer received 48 Expressions of Interest for its inaugural funding round and EOIs for the second round open on September 21. Details at biointelect.com\/biointelect-venturer<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Clinical-stage biotech ENA Respiratory has raised $2.98 million from the government-backed Biointelect Venturer program to expand testing of…\n","protected":false},"author":2,"featured_media":605187,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[2669,1756,163,85,46,43],"class_list":["post-605186","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-biotech","tag-funding","tag-health","tag-il","tag-israel","tag-news"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/605186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=605186"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/605186\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/605187"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=605186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=605186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=605186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}